Literature DB >> 12213890

Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7alpha-hydroxylase mRNAs in human liver.

Mats Rudling1, Bo Angelin, Lars Ståhle, Eva Reihnér, Staffan Sahlin, Hans Olivecrona, Ingemar Björkhem, Curt Einarsson.   

Abstract

To characterize the coordinate regulation of cholesterol metabolism in human liver, we simultaneously quantified mRNA levels of cholesterol 7alpha-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), and low- density lipoprotein receptors (LDLRs) in liver biopsies from 76 patients undergoing cholecystectomy. The three transcript levels were not different between untreated gallstone and gallstone-free patients and not significantly altered by 10-d exclusion of dietary cholesterol. Treatment with chenodeoxycholic acid suppressed CYP7A1 and to a lesser extent HMGR mRNA levels. Cholestyramine treatment increased CYP7A1, but also HMGR and LDLR mRNA, and statins only increased HMGR mRNA. Resin + statin treatment increased all mRNA species. In untreated patients, the mRNA levels of HMGR and LDLR were more strongly correlated (r = +0.60) than those of CYP7A1 and HMGR (r = +0.49) or CYP7A1 and LDLR (r = +0.21). In the treated patients, in whom bile acid synthesis was suppressed or stimulated, mRNA levels of CYP7A1 and HMGR (r = +0.84) as well as CYP7A1 and LDLR (r = +0.62) were more strongly correlated than those of HMGR and LDLR (r = +0.59). The coordinate control of HMGR and LDLR mRNA levels reflects their common regulation by shared transcriptional activation. In contrast, following changes in bile acid flux through the liver, CYP7A1 gene expression becomes a strong modulator of hepatic cholesterol metabolism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213890     DOI: 10.1210/jc.2002-012041

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Authors:  Abhay P Sagare; Rashid Deane; Berislav V Zlokovic
Journal:  Pharmacol Ther       Date:  2012-07-20       Impact factor: 12.310

2.  Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.

Authors:  André J Tremblay; Benoît Lamarche; Valéry Lemelin; Lizbeth Hoos; Suzanne Benjannet; Nabil G Seidah; Harry R Davis; Patrick Couture
Journal:  J Lipid Res       Date:  2010-12-01       Impact factor: 5.922

3.  No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.

Authors:  Xiaoqiang Xiang; Juha Vakkilainen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Eur J Clin Pharmacol       Date:  2011-06-08       Impact factor: 2.953

4.  Atorvastatin up-regulate toxicologically relevant genes in rainbow trout gills.

Authors:  Kathrin Sabine Ellesat; Tor Fredrik Holth; Marcin Włodzimierz Wojewodzic; Ketil Hylland
Journal:  Ecotoxicology       Date:  2012-05-04       Impact factor: 2.823

5.  Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.

Authors:  Moumita Ghosh; Cecilia Gälman; Mats Rudling; Bo Angelin
Journal:  J Lipid Res       Date:  2014-12-22       Impact factor: 5.922

6.  Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.

Authors:  Paolo Parini; Ulf Gustafsson; Matt A Davis; Lilian Larsson; Curt Einarsson; Martha Wilson; Mats Rudling; Hiroshi Tomoda; Satoshi Omura; Staffan Sahlin; Bo Angelin; Lawrence L Rudel; Mats Eriksson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-13       Impact factor: 8.311

Review 7.  Gene activation regresses atherosclerosis, promotes health, and enhances longevity.

Authors:  Pauli V Luoma
Journal:  Lipids Health Dis       Date:  2010-07-06       Impact factor: 3.876

Review 8.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 9.  The use of stable and radioactive sterol tracers as a tool to investigate cholesterol degradation to bile acids in humans in vivo.

Authors:  Marco Bertolotti; Andrea Crosignani; Marina Del Puppo
Journal:  Molecules       Date:  2012-02-16       Impact factor: 4.411

10.  Identification of liver CYP51 as a gene responsive to circulating cholesterol in a hamster model.

Authors:  Haiqiu Huang; Zhuohong Xie; Wallace Yokoyama; Liangli Yu; Thomas T Y Wang
Journal:  J Nutr Sci       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.